ANKRD22 is a novel therapeutic target for gastric mucosal injury

Biomedicine & Pharmacotherapy

Yongliang Zhu¹  Youhe Wu¹  Rui Wang¹  Sheng Yao¹  Yue Zhu² 

[1] Laboratory of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China;School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China;

关键词: ANKRD22;    Gastric mucosal injury;    Epithelial stem cells;    Inflammation;    Mitochondria;    Ca2+;   

DOI  :  

来源: DOAJ

【 摘 要 】

Ankyrin repeat domain 22 (ANKRD22) is a nuclear-encoded mitochondrial membrane protein that is highly expressed in normal gastric mucosal epithelial cells and activated macrophages. As a regulator of mitochondrial Ca2+, ANKRD22 could help repair damaged gastric mucosa by promoting the mobilization of LGR5+ gastric epithelial cells via the upregulation of Wnt/β-catenin pathway activity in a mouse model. Furthermore, the inhibition of ANKRD22 alleviated the macrophage activation-mediated inflammatory response by reducing the phosphorylation of nuclear factor of activated T cells (NFAT). ANKRD22 plays a significant role in the repair of gastric mucosal damage and may become an ideal novel target for the treatment of gastric mucosal injury. However, there is no systematic introduction to ANKRD22 targeting. Therefore, we wrote this review to elaborate the functional mechanism of ANKRD22 in gastric mucosal injury and to analyze its potential application value in clinical therapy.

【 授权许可】

Unknown